pufa 20:4

PUFA 20:4, commonly known as arachidonic acid (ARA), is a long‑chain polyunsaturated fatty acid of the omega‑6 family. It is a 20‑carbon fatty acid with four cis double bonds (20:4n‑6) that is a structural component of phospholipids within cell membranes throughout the body, particularly in the brain, muscle, liver, and immune cells. Unlike essential fatty acids such as linoleic acid (18:2n‑6), which must be consumed in the diet, arachidonic acid can be synthesized endogenously from linoleic acid via desaturation and elongation reactions in the liver and other tissues. However, it is also obtained directly from animal‑based dietary sources. In cellular biology, ARA is esterified into membrane phospholipids and released by the action of phospholipase A2 enzymes in response to physiological signals to serve as a precursor for a diverse family of eicosanoids. These include prostaglandins, thromboxanes, leukotrienes, lipoxins, and other oxidized derivatives that serve as potent autocrine and paracrine signaling molecules. Its discovery in the early 20th century stemmed from lipid biochemistry studies identifying fatty acid components of phospholipids. ARA is distinctively abundant in mammalian tissues compared to many other PUFAs, reflecting its importance in multiple tissues. Because of its role in generating bioactive lipid mediators, arachidonic acid is deeply involved in immune responses and inflammatory processes. However, its involvement is complex: certain metabolites promote inflammation necessary for pathogen defense and wound healing, while others contribute to resolution of inflammation and homeostasis. In the central nervous system, ARA is a key constituent of neuronal membrane phospholipids, where it influences membrane fluidity, receptor function, and neurotransmission dynamics essential for cognition and synaptic plasticity. Muscle cells also store significant ARA, where it participates in signaling pathways that affect protein synthesis, muscle repair, and adaptation to exercise stress. Although endogenous synthesis from linoleic acid provides a baseline supply, dietary intake helps support physiological pools, especially when conversion from precursors is limited by genetics, age, or dietary composition. In typical Western diets, arachidonic acid intake has been estimated at approximately 50 to 300 mg per day, primarily from meats, eggs, and seafood, but no formal Dietary Reference Intake has been established by NIH or the Institute of Medicine specifically for arachidonic acid itself.

Arachidonic acid is best known for its role as a precursor for eicosanoid synthesis. Eicosanoids include prostaglandins, thromboxanes, leukotrienes, and lipoxins, each of which plays pivotal roles in inflammation, immunity, platelet function, and vascular tone. For example, prostaglandin E2 (PGE2) mediates vasodilation and fever responses, while thromboxane A2 (TXA2) promotes platelet aggregation and vasoconstriction. These signaling pathways illustrate how ARA metabolites contribute to the acute inflammatory response necessary for pathogen clearance and tissue repair. When cell membranes are disrupted by injury or immune activation, phospholipase A2 releases free arachidonic acid, which is then enzymatically converted into active mediators via cyclooxygenase (COX) and lipoxygenase (LOX) pathways. In the immune system, arachidonic acid is crucial for leukocyte function. Eicosanoids modulate chemotaxis, cytokine production, and phagocyte activation, shaping the innate immune response to infections. Balanced ARA metabolism allows effective immune surveillance without excessive, chronic inflammation that contributes to pathology. In the nervous system, ARA’s integration into phospholipids affects membrane fluidity and neuronal signaling. ARA and its metabolites are involved in synaptic plasticity and neurotransmission processes underlying memory and learning. Some research suggests that ARA plays roles in cognitive processes and neurodevelopment, particularly in early life when demands for structural lipid components are high. Another emerging area of interest is the role of arachidonic acid in muscle physiology. During and after exercise, ARA‑derived signaling molecules influence muscle remodeling and recovery pathways. Some trials have investigated supplemental ARA in resistance‑trained adults, showing increases in blood ARA content with doses as low as 80 mg per day, though clear functional outcomes require further evidence. Higher ARA intake has been studied up to 1000–1500 mg per day without marked adverse effects on blood lipids or inflammation markers in adults, although definitive recommendations cannot yet be made. The interplay between arachidonic acid and other PUFAs is also vital: an imbalance favoring omega‑6 over omega‑3 fatty acids may shift eicosanoid profiles toward pro‑inflammatory states, highlighting the need for balanced dietary fat intake. Appropriate levels of omega‑3 fatty acids such as EPA and DHA can compete with arachidonic acid for enzymatic conversion, moderating inflammatory responses and contributing to cardiovascular and metabolic health outcomes. Thus, while ARA–derived mediators can contribute to inflammatory signaling, this capacity is fundamental to normal physiological processes rather than inherently pathological when balanced with other dietary factors.

Unlike essential fatty acids such as linoleic acid, arachidonic acid itself does not have an officially established Recommended Dietary Allowance (RDA) from the National Institutes of Health or the Food and Nutrition Board. Instead, dietary reference values exist for total polyunsaturated fatty acids and precursor omega‑6 essential fatty acids like linoleic acid. The human body can synthesize arachidonic acid from linoleic acid through desaturation and elongation, and for most healthy adults consuming sufficient linoleic acid, endogenous production meets physiological needs. Typical dietary intake of arachidonic acid in Western populations has been estimated between 50 and 300 mg per day, derived mainly from animal sources such as meats, eggs, and some fish. There is no Tolerable Upper Intake Level set for arachidonic acid, but research indicates that supplemental intakes in adults up to approximately 1000–1500 mg per day appear not to adversely affect traditional markers of inflammation or lipid profiles in short‑term studies. However, these data are limited and do not constitute formal intake recommendations. Age, sex, growth status, and dietary composition influence needs and metabolism. In infancy, arachidonic acid is considered critical for brain and visual development; thus, it is commonly included alongside DHA in infant formulas to approximate breast milk composition. Factors that may increase requirements include rapid growth, recovery from injury, or chronic illness where membrane turnover and immune activation are elevated. Conversely, individuals on strictly plant‑based diets receive little preformed arachidonic acid from food and rely entirely on endogenous synthesis; while most adults can maintain adequate status through conversion from linoleic acid, preliminary evidence suggests that in early life stages such as infancy and childhood, conversion may not suffice, which is why dietary intake during those stages is often emphasized.

True deficiency of arachidonic acid is rare in omnivorous adults because the body synthesizes it from dietary linoleic acid and because typical diets provide some preformed ARA. However, inadequate intake or impaired metabolism can theoretically lead to lower tissue levels, which may manifest as impaired inflammatory and immune responses. Clinical signs attributed to relative arachidonic acid deficiency include skin problems such as dryness, eczema, or scaliness; brittle hair; joint discomfort or pain; and increased susceptibility to infections due to suboptimal immune cell signaling. Neurological effects such as mood disturbances, cognitive symptoms, or fatigue have been hypothesized in contexts of severely low ARA status, although evidence is limited. In infants and young children, insufficient arachidonic acid can affect neural and visual development, which is why both ARA and DHA are included in many infant formulas. Certain conditions that impair fat absorption—such as cystic fibrosis, inflammatory bowel disease, or genetic defects in desaturase enzymes—could reduce endogenous synthesis and contribute to functional insufficiency. Diagnosis of ARA deficiency requires specialized fatty acid profiling of blood or erythrocyte membranes, as typical clinical tests do not routinely measure individual long‑chain fatty acids. Reference ranges have been proposed by laboratory panels expressing arachidonic acid as a percentage of total essential fatty acids, with some suggesting optimal levels approximately 7–19% of total EFAs, but standardized clinical cutoffs are not established. Thus, clinical evaluation must consider dietary intake, symptoms, and broader fatty acid balance, particularly omega‑6 to omega‑3 ratios, to assess whether ARA status may be contributing to health concerns.

Arachidonic acid is found predominantly in animal‑based foods. It is virtually absent from most plant foods because plants lack the enzymatic pathways to synthesize long‑chain 20‑carbon PUFAs, with rare exceptions such as certain algae species. The richest sources are organ meats and certain meats where cell membranes are abundant. Below is a table of high arachidonic acid foods with approximate amounts per 100‑gram serving: Organ meats such as beef liver and kidneys provide among the highest natural levels of arachidonic acid. Muscle meats such as chicken (especially dark meat), turkey, and beef also contribute meaningful amounts. Egg yolks contain moderate arachidonic acid, with whole eggs being a convenient source. Certain fish like salmon contain both omega‑3 and omega‑6 PUFAs, including ARA, though amounts are lower relative to omega‑3 content. Dairy products contribute smaller amounts yet can cumulatively contribute to intake in mixed diets. Because arachidonic acid resides largely in membrane phospholipids, cuts rich in cell membranes—such as heart or kidney—tend to contain higher concentrations. Incorporating a variety of these foods alongside balanced omega‑3 sources helps maintain appropriate fatty acid balance. (Note: amounts listed are approximate and will vary by animal diet and preparation.) In contrast, plant foods generally provide linoleic acid, the precursor for endogenous arachidonic acid synthesis rather than preformed ARA itself. Oils rich in linoleic acid include safflower, corn, and sunflower oils, but conversion rates to ARA are limited in humans, particularly in adults.

Arachidonic acid is absorbed in the small intestine along with other dietary fats. Ingested triglycerides and phospholipids containing ARA are emulsified by bile salts, facilitating incorporation into micelles that are taken up by enterocytes. Within enterocytes, ARA and other fatty acids are re‑esterified into triglycerides and phospholipids and packaged into chylomicrons for lymphatic transport into circulation. This process is generally efficient, similar to other long‑chain polyunsaturated fatty acids, but may be compromised in conditions that impair fat digestion or bile production. Once in circulation, ARA is distributed to tissues and incorporated into cell membrane phospholipids. Competing fatty acids influence bioavailability and metabolism. Omega‑3 fatty acids such as EPA compete with arachidonic acid for incorporation into membranes and for enzymatic conversion via cyclooxygenase and lipoxygenase pathways. A diet high in omega‑3s can shift membrane composition and eicosanoid production toward less pro‑inflammatory profiles. Conversely, diets disproportionately high in omega‑6 relative to omega‑3 fatty acids may favor ARA incorporation and its downstream products. Factors such as age, genetics, and health status also influence how effectively ARA is utilized; for example, infants and young children have higher demands for long‑chain PUFAs due to rapid neural development, affecting tissue distribution and needs. Additionally, certain medications that inhibit enzymes in ARA metabolism (e.g., cyclooxygenase inhibitors) can alter the fate of ingested arachidonic acid.

Supplementation with arachidonic acid is a topic of research rather than established clinical guidance. Because the body can synthesize ARA from linoleic acid and typical diets provide some preformed ARA, supplementation is not broadly recommended for healthy adults. Some studies in specific contexts have investigated supplemental ARA for potential benefits such as supporting muscle growth and recovery in resistance training or cognitive outcomes in aging populations, but results are inconsistent and not sufficient to support routine use. Doses used in research range from ~80 mg/day to over 1000 mg/day, with increases in blood ARA fractions observed, but clear clinical benefits remain under study. Individuals with limited intake of animal products (e.g., strict vegetarians) may have lower dietary ARA and could consider balanced essential fatty acid intake to support endogenous synthesis, though routine supplemental ARA is not commonly prescribed. In infancy, formulas fortified with ARA and DHA are standard to mimic breast milk composition and support neural development. Choosing a supplement, when indicated, requires attention to form (typically triglyceride or phospholipid forms), purity, and balance with omega‑3 sources to avoid skewing inflammatory profiles. Healthcare guidance should consider individual dietary patterns, fatty acid status, and health goals. For most adults, focusing on a dietary pattern that includes modest amounts of high‑quality animal proteins and simultaneous intake of omega‑3 rich foods is a more balanced approach than targeting supplementation of arachidonic acid alone.

There is no officially established Tolerable Upper Intake Level (UL) for arachidonic acid. Research studies have administered intakes up to approximately 1000–1500 mg per day in adults without consistent adverse effects on markers such as blood lipids, platelet aggregation, or inflammation, though evidence is limited. At very high intakes, particularly in the context of diets high in omega‑6 fats relative to omega‑3s, an elevated arachidonic acid pool may favor increased production of pro‑inflammatory eicosanoids, which could contribute to chronic inflammatory states if unbalanced by sufficient omega‑3 fatty acids. Excessive arachidonic acid could theoretically exacerbate conditions such as arthritis, cardiovascular disease, or other inflammation‑related disorders, though causality is not established and depends on broader dietary and metabolic context. As with other fatty acids, caloric excess from high‑fat diets may contribute to weight gain and metabolic complications.

Arachidonic acid metabolism intersects with several pharmaco‑logical pathways. Non‑steroidal anti‑inflammatory drugs (NSAIDs) such as aspirin, ibuprofen, and other COX inhibitors target cyclooxygenase enzymes that convert free arachidonic acid into prostaglandin precursors, thereby reducing inflammation and pain responses. These drugs effectively alter the balance of ARA‑derived eicosanoids and must be considered when interpreting inflammatory status or fatty acid metabolism. Similarly, selective COX‑2 inhibitors (coxibs) influence ARA conversion and modulate specific prostaglandin pathways. Medications that affect phospholipase A2 activity, corticosteroids, and leukotriene pathway inhibitors also impact arachidonic acid liberation and downstream signaling. Additionally, high doses of omega‑3 supplements (EPA/DHA) can compete with arachidonic acid for enzymatic pathways, potentially influencing medication effects that target these same enzymes. Clinicians should consider these interactions when managing inflammation, cardiovascular risk, or immune conditions.

Common Forms: triglyceride ARA supplements, phospholipid ARA

Typical Doses: 80–1500 mg/day in research

When to Take: with meals containing fats

Best Form: phospholipid form

⚠️ Interactions: NSAIDs COX inhibitors, omega‑3 EPA/DHA competition